viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies recruits pharma exec Andy Nixon to board

Dr Nixon is a vice-president of Biotherapeutics Molecule Discovery at Boehringer Ingelheim, who boasts expertise in biologic drug discovery

empty board room
ImmunoPrecise’s board is now made up of seven members

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF), the Canadian antibody discovery company, told investors Thursday it has tapped Andy Nixon, a senior executive with the German pharmaceutical company Boehringer Ingelheim, as a member of its board.

Nixon, a vice-president of Biotherapeutics Molecule Discovery at Boehringer Ingelheim, boasts expertise in biologic drug discovery and non-clinical development work as well.

Also on his list of career accomplishments is his leading of the research team that developed the US pharmaceutical group Dyax’s pipeline drug candidates and helped to trigger rival Shire’s acquisition of Dyax in 2016 for $5.9 billion.

READ: ImmunoPrecise and TetraGenetics extend alliance to discover therapeutic antibodies for autoimmune disease

“As ImmunoPrecise advances its strategy for accelerate growth in the custom therapeutic antibody space, and for sustainable shareholder value creation, Dr. Nixon brings a unique depth of experience and expertise that is directly relevant to ImmunoPrecise,” said Jennifer Bath, ImmunoPrecise’s CEO and president.

“We are pleased to have Dr. Nixon support ImmunoPrecise through the next phase of our development,” Bath added.

Now that Nixon has joined, ImmunoPrecise’s board will be made up of seven members.

The Victoria, British Columbia-headquartered company provides global antibody services ranging from target analysis to pre-clinical studies.

ImmunoPrecise is concentrating on discovering the most relevant next-generation antibodies that it feels has the highest probability of succeeding through clinical trials.

ImmunoPrecise shares held steady at C$0.82 in morning Canadian trade on Thursday.

Contact Ellen Kelleher at [email protected]

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 1.41 CAD

Market: TSX-V
Market Cap: $98.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...



ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 2/4/19

2 min read